254
Participants
Start Date
March 31, 2009
Primary Completion Date
October 31, 2009
Study Completion Date
January 31, 2010
exenatide once weekly
subcutaneous injection, 2.0mg, once a week
exenatide twice daily
subcutaneous injection; 5mcg (4 weeks) and 10mcg (20 weeks); twice a day
Research Site, Birmingham
Research Site, Mesa
Research Site, Peoria
Research Site, Artesia
Research Site, Concord
Research Site, Encino
Research Site, Greenbrae
Research Site, La Mesa
Research Site, Walnut Creek
Research Site, DeLand
Research Site, Hialeah
Research Site, Miami
Research Site, New Port Richey
Research Site, Palm Harbor
Research Site, Chicago
Research Site, Avon
Research Site, Evansville
Research Site, Lexington
Research Site, Paducah
Research Site, Detroit
Research Site, Edina
Research Site, St Louis
Research Site, Butte
Research Site, New Hyde Park
Research Site, Rochester
Research Site, Raleigh
Research Site, Statesville
Research Site, Cincinnati
Research Site, Delaware
Research Site, Mentor
Research Site, Eugene
Research Site, Rapid City
Research Site, Austin
Research Site, Corpus Christi
Research Site, San Antonio
Research Site, Burke
Research Site, Manassas
Research Site, Richmond
Research Site, Olympia
Research Site, Spokane
Research Site, Tacoma
Lead Sponsor
Eli Lilly and Company
INDUSTRY
AstraZeneca
INDUSTRY